Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6418-6428

  Gao, Huiping ^a,b   Li, Kesang ^b   Tu, Hong ^b   Pan, Xiaorong ^b   Jiang, Hua ^b   Shi, Bizhi ^b   Kong, Juan ^b   Wang, Hongyang ^b,c,d   Yang, Shengli ^b   Gu, Jianren ^b   Li, Zonghai ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d National Center for Liver Cancer   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; GLYPICAN 3; LENTIVIRUS VECTOR; CYTOKINE; GLYPICAN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; NANOBODY; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; GENE ORDER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; LIVER NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE ORDER; GENETIC VECTORS; GLYPICANS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; LIVER NEOPLASMS; MICE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919723297     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1170     Document Type: Article

References (33)

1. El-Serag H.B., Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
3. Llovet JM, Ricci S, Mazzaferro V., Hilgard P, Gane E, Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
5. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013;13:525-41.
6. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
7. Baumhoer D, Tornillo L, Stadlmann S., Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008;129: 899-906.
8. Nakano K, Yoshino T, Nezu J.I., Tsumoda H., Igawa T, Konishi H, inventor; Anti-Glypican 3 antibody. United States patent US 20070190599. 2007 Aug 16.
9. Phung Y, Gao W, Man Y.G., Nagata S., Ho M. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs 2012;4:592-9.
10. Feng M, Gao W, Wang R., Chen W, Man YG, Figg W.D., et al. Therapeutically targeting glypican-3 via a conformation-specific singledomain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2013;110:E1083-91.
11. Gao W, Kim H, Feng M., Phung Y, Xavier CP, Rubin J.S., et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 2014;60:576-87.
12. Sawada Y, Yoshikawa T, Nobuoka D., Shirakawa H, Kuronuma T, Motomura Y., et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-96.
13. Feng MQ, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 2014;588:377-82.
14. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams T.A., Morikawa H., Ohishi N, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013;19: 920-8.
15. Zhou M, Wang H, Zhou K.K., Luo XY, Pan XR, Shi BZ, et al. A novel EGFR isoform confers increased invasiveness on cancer cells. Cancer Res 2013;73:7056-67.
16. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004;22: 589-94.
17. Wang H, Zhou M, Shi B., Zhang Q, Jiang H, Sun Y., et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011;13: 461-71.
18. Pinthus JH, Waks T, Malina V., Kaufman-Francis K, Harmelin A, Aizenberg I., et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004; 114:1774-81.
19. Maliar A, Servais C, Waks T., Chmielewski M, Lavy R, Altevogt P., et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012; 143:1375-84.e1-5.
20. Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem J 2008;410:503-11.
21. Hippo Y, Watanabe K, Watanabe A., Midorikawa Y, Yamamoto S, Ihara S., et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
22. + T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012;109:4592-7.
23. Chapuis AG, Ragnarsson GB, Nguyen H.N., Chaney CN, Pufnock JS, Schmitt TM, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013;5:174ra27.
24. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007;179: 4910-8.
25. Carpenito C, Milone MC, Hassan R, Simonet J.C., Lakhal M., Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106:3360-5.
26. Chen M, Li G, Yan J., Lu X, Cui J, Ni Z., et al. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 2013;423:105-11.
27. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing Erbb2. Mol Ther 2010;18:843-51.
28. Di Stasi A., Tey SK, Dotti G, Fujita Y., Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673-83.
29. Russo V, Bondanza A, Ciceri F., Bregni M, Bordignon C, Traversari C., et al. A dual role for genetically modified lymphocytes in cancer immunotherapy. Trends Mol Med 2012;18: 193-200.
30. Kloss CC, Condomines M, Cartellieri M., Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31:71-5.
31. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert offtarget immunotherapy responses. Sci Transl Med 2013;5:215ra172.
32. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003;4: 104-9.
33. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125: 89-97.